Eurofins Genomics Blue Heron, a nucleic acid synthesis provider, attests that it is compliant with the US Framework for Nucleic Acid Synthesis Screening according to the October 2023 Executive Order 14110, as pertains to nucleic acid synthesis providers supporting federally-funded customers. If, in the event that Eurofins Genomics Blue Heron becomes non-compliant, this attestation will be updated as soon as possible.
In addition, Eurofins Genomics Blue Heron is a proud member of the International Gene Synthesis Consortium, an independent, industry-led group of gene synthesis companies aimed for the goal of developing and applying a standardized screening protocol to DNA synthesis orders. These guidelines have been designed to be compliant with Executive Order 14110, in addition to providing additional rules and guidelines regarding screening of both ordered sequences and the customers that order them, in the name of increased safety and biosecurity.
For any additional information, any questions may be sent to the support team at bhbcs@blueheronbio.com, or by phone to 425-368-5000.
Additional links
https://www.whitehouse.gov/wp-content/uploads/2024/04/Nucleic-Acid_Synthesis_Screening_Framework.pdf